SPRB Key Statistics, Chart & Performance
The current stock price of SPRB is 79.99 USD. In the past month the price decreased by -6.63%. In the past year, price increased by 16655.3%.
SPRB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B |
Related stock screener links
About SPRB
Company Profile
Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company is headquartered in South San Francisco, California and currently employs 9 full-time employees. The company went IPO on 2020-10-09. The firm has acquired an exclusive worldwide license agreement for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). The TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with modified human insulin-like growth factor 2 via an amino acid linker. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. The firm's pipeline also includes Tildacerfont and Cortibon for the treatment of Major Depressive Disorder, SPR202 for the treatment of Congenital Adrenal Hyperplasia and SPR204 for the treatment of Post-Bariatric Hypoglycemia.
Company Info
SPRUCE BIOSCIENCES INC
611 Gateway Boulevard, Suite 740
South San Francisco CALIFORNIA 94104 US
CEO: Richard King
Employees: 9
Phone: 14156554168
SPRUCE BIOSCIENCES INC / SPRB FAQ
Can you describe the business of SPRUCE BIOSCIENCES INC?
Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company is headquartered in South San Francisco, California and currently employs 9 full-time employees. The company went IPO on 2020-10-09. The firm has acquired an exclusive worldwide license agreement for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). The TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with modified human insulin-like growth factor 2 via an amino acid linker. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. The firm's pipeline also includes Tildacerfont and Cortibon for the treatment of Major Depressive Disorder, SPR202 for the treatment of Congenital Adrenal Hyperplasia and SPR204 for the treatment of Post-Bariatric Hypoglycemia.
Can you provide the latest stock price for SPRUCE BIOSCIENCES INC?
The current stock price of SPRB is 79.99 USD. The price increased by 8.53% in the last trading session.
Does SPRB stock pay dividends?
SPRB does not pay a dividend.
What is the ChartMill technical and fundamental rating of SPRB stock?
SPRB has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the valuation of SPRUCE BIOSCIENCES INC (SPRB) based on its PE ratio?
SPRUCE BIOSCIENCES INC (SPRB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-84.83).
Is SPRUCE BIOSCIENCES INC (SPRB) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SPRB.
What is the next earnings date for SPRB stock?
SPRUCE BIOSCIENCES INC (SPRB) will report earnings on 2026-04-13, after the market close.
SPRB Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to SPRB. When comparing the yearly performance of all stocks, SPRB is one of the better performing stocks in the market, outperforming 99.99% of all stocks.
SPRB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SPRB. While SPRB seems to be doing ok healthwise, there are quite some concerns on its profitability.
SPRB Financial Highlights
Over the last trailing twelve months SPRB reported a non-GAAP Earnings per Share(EPS) of -84.83. The EPS decreased by -19.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -312.67% | ||
| ROE | -888.95% | ||
| Debt/Equity | 0 |
SPRB Forecast & Estimates
8 analysts have analysed SPRB and the average price target is 213.69 USD. This implies a price increase of 167.15% is expected in the next year compared to the current price of 79.99.
For the next year, analysts expect an EPS growth of 85.84% and a revenue growth -100% for SPRB